Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kinaxo Biotechnologies has entered into a second collaboration with Roche Diagnostics in Penzberg, Germany. As per the agreement, Kinaxo will apply its phosphoproteomics technology, PhosphoScout, to support targeted treatment approaches currently under development at Roche.
Subscribe to our email newsletter
Kinaxo’s phosphoproteomics platform, PhosphoScout enables the identification of regulated protein phosphorylation sites in response to therapeutic antibody or kinase inhibitor treatment. Using the quantitative mass spectrometry, up to 15,000 phosphorylation sites can be monitored in a single experiment, thereby facilitating analysis of the phosphoproteome in patient samples, animal models and cell culture on a global scale.
Unlike immunoassays, PhosphoScout does not require antibodies for detection, thus enabling unbiased, comprehensive phosphoproteome analyses across entire signaling pathways. This positions PhosphoScout as an upcoming technology for drug mode of action analysis and the stratification of cancer patients receiving targeted therapies, said the company.